Targeting the endothelin axis in scleroderma renal crisis: Rationale and feasibility

QJM: An International Journal of Medicine

Volumn 106, Issue 9, 2013, Pages 839-848

  Penn, H ^a   Quillinan, N ^a,b   Khan, K ^a   Chakravarty, K ^c   Ong, V H ^a   Burns, A ^a   Denton, C P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF BEDFORDSHIRE   (United Kingdom)

^c QUEEN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BOSENTAN; CD31 ANTIGEN; CD34 ANTIGEN; CYCLOSPORIN A; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; GLIBENCLAMIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA1; VON WILLEBRAND FACTOR;

ADULT; ANEMIA; ARTICLE; BRAIN DISEASE; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLOMERULONEPHRITIS; HEART ATRIUM FIBRILLATION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; INTERSTITIUM; KIDNEY BIOPSY; LEG EDEMA; LIVER FUNCTION TEST; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PERICARDITIS; PILOT STUDY; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; PULMONARY HYPERTENSION; REBOUND; SCLERODERMA; SCLERODERMA RENAL CRISIS; SIDE EFFECT; SYSTEMIC SCLEROSIS; THROMBOCYTOPENIA; UPREGULATION; UREMIA; VASCULAR LESION;

ACUTE KIDNEY INJURY; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CASE-CONTROL STUDIES; ENDOTHELIN-1; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PILOT PROJECTS; RECEPTOR, ENDOTHELIN A; SCLERODERMA, SYSTEMIC; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84889049254     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hct111     Document Type: Article

References (21)

1. Steen VD, Costantino JP, Shapiro AP, Medsger TA Jr. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990; 113:352-7.
2. Penn H, Howie AJ, Kingdon EJ, Bunn CC, Stratton RJ, Black CM, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 2007; 100:485-94.
3. Hesselstrand R, Scheja A, Wuttge DM. Scleroderma renal crisis in a Swedish systemic sclerosis cohort: survival, renal outcome, and RNA polymerase III antibodies as a risk factor. Scand J Rheumatol 2012; 41:39-43.
4. Steen VD. Scleroderma renal crisis. Rheum Dis Clin North Am 1996; 22:861-78.
5. Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007; 66:754-63.
6. Kahaleh MB. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum 1991; 34:978-83.
7. Morelli S, Ferri C, Polettini E, Bellini C, Gualdi GF, Pittoni V, et al. Plasma endothelin-1 levels, pulmonary hypertension, and lung fibrosis in patients with systemic sclerosis. Am J Med 1995; 99:255-60.
8. Kadono T, Kikuchi K, Sato S, Soma Y, Tamaki K, Takehara K. Elevated plasma endothelin levels in systemic sclerosis. Arch Dermatol Res 1995; 287:439-42.
9. Odoux C, Crestani B, Lebrun G, Rolland C, Aubin P, Seta N, et al. Endothelin-1 secretion by alveolar macrophages in systemic sclerosis. AmJ Respir Crit CareMed 1997; 156:1429-35.
10. Vancheeswaran R, Magoulas T, Efrat G, Wheeler-Jones C, Olsen I, Penny R, et al. Circulating endothelin-1 levels in systemic sclerosis subsets-a marker of fibrosis or vascular dysfunction? J Rheumatol 1994; 21:1838-44.
11. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346:896-903.
12. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358:1119-23.
13. Galie N, Grigioni F, Bacchi-Reggiani L, Ussia GP, Parlangeli R, Catanzariti P, et al. Relation of endothelin-1 to survival in patients with primary pulmonary hypertension. Eur J Clin Invest 1996; 26(Suppl. 1):A48.
14. Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006; 65:1336-40.
15. Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004; 50:3985-93.
16. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23:581-90.
17. Actelion Pharmaceuticals. Summary of Product Characteristics for Bosentan. http://www.actelion.com/documents/ corporate/smpc_pils/Tracleer_SmPC.pdf (16 May 2013, date last accessed).
18. Mouthon L, Mehrenberger M, Teixeira L, Fakhouri F, Berezne A, Guillevin L, et al. Endothelin-1 expression in scleroderma renal crisis. Hum Pathol 2011; 42:95-102.
19. Kobayashi H, Nishimaki T, Kaise S, Suzuki T, Watanabe K, Kasukawa R, et al. Immunohistological study endothelin-1 and endothelin-A and B receptors in two patients with scleroderma renal crisis. Clin Rheumatol 1999; 18:425-7.
20. Ahn D, Ge Y, Stricklett PK, Jill P, Taylor D, Hughes AK, et al. Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention. J Clin Invest 2004; 114:504-11.
21. Bohm F, Pernow J, Lindstrom J, Ahlborg G. ETA receptors mediate vasoconstriction, whereas ETB receptors clear endothelin-1 in the splanchnic and renal circulation of healthy men. Clin Sci 2003; 104:143-51.